Sign In
Buy QLGN
$3.21
+0 (+0%)
At Close: Feb 17, 2026
Qualigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
07:30am, Wednesday, 15'th Sep 2021
CARLSBAD, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential
Qualigen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07:30am, Wednesday, 08'th Sep 2021
CARLSBAD, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential
Why Qualigen Therapeutics (QLGN) Stock Plunging After Q2 Update
10:01am, Tuesday, 17'th Aug 2021
Tucked in its Q2 earnings release, Qualigen Therapeutics Inc (NASDAQ: QLGN) announced deprioritizing the QN-165 COVID-19 program, sending shares to fall to a 52-week low. In July, the Company file
Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19
07:30am, Wednesday, 14'th Jul 2021
CARLSBAD, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral d
Qualigen Therapeutics, Inc. to Present at the LD Micro Invitational XI Conference
07:30am, Wednesday, 02'nd Jun 2021
CARLSBAD, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral d
Qualigen Therapeutics, Inc. Appoints Tariq Arshad, MD, MBA as Chief Medical Officer
07:30am, Wednesday, 19'th May 2021
New Position Created to Deepen Clinical Expertise and Advance Pipeline Therapeutic Programs
Qualigen Therapeutics, Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update
01:35pm, Friday, 14'th May 2021
Conference call scheduled for May 18, 2021 at 4:10 p.m. EDT.
Qualigen Therapeutics Plans to Combat COVID-19 Variants
01:16pm, Monday, 19'th Apr 2021
Qualigen Therapeutics Inc (NASDAQ: QLGN) was one of the sponsors for the Benzinga Biotech Global Small Cap Conference that took place on March 24-25, 2021. The information contained in this article in
Why Is Qualigen Stock Trading Lower Today?
07:40am, Monday, 12'th Apr 2021
Qualigen Therapeutics Inc (NASDAQ: QLGN) shares are ticking lower as the company withdrew the FDA Emergency Use Authorization (EUA) application for its FastPack SARS-CoV-2 IgG diagnostic test for CO
Qualigen Therapeutics, Inc. Promotes Shishir Sinha to Chief Operating Officer Position
08:30am, Tuesday, 09'th Mar 2021
CARLSBAD, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infect
Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference
08:30am, Monday, 08'th Mar 2021
CARLSBAD, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral
Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL
08:30am, Monday, 01'st Mar 2021
CARLSBAD, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral
Qualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct Offering
03:07pm, Friday, 18'th Dec 2020
CARLSBAD, Calif., Dec. 18, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with a single institutiona
Qualigen Therapeutics Completes Recertification of Existing AS1411 Drug Supply for Use in Upcoming Clinical Trials
09:00am, Wednesday, 02'nd Dec 2020
CARLSBAD, Calif., Dec. 2, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces that it has completed the recertification of its supply of AS1411, and has begun final formulation a
